Lilly Migraine Treatment Moves Forward

Posted: Updated:
Lilly plans to present trial results at scientific meetings and publications over the next year. Lilly plans to present trial results at scientific meetings and publications over the next year.

Indianapolis-based Eli Lilly and Co. (NYSE: LLY) says its second Phase 3 study of an oral migraine treatment has yielded positive results. Lilly says as a result of the positive outcome for lasmiditan, the company plans to submit a New Drug Application with the U.S. Food and Drug Administration in the second half of 2018.

Lilly says the treatment met its primary endpoint in the SPARTAN study, which showed that a greater percentage of patients treated with lasmiditan were migraine pain-free compared to placebo after two hours of taking the first dose. The drug also met is secondary endpoint, which showed that a "statistically significantly greater percentage" of patients were free of their most bothersome symptoms, such as nausea and sensitivity to sound or light.

"Lasmiditan represents the first significant innovation in the acute treatment of migraine in more than 20 years, and could provide a much-needed new treatment option for the 36 million Americans living with migraine," said Christi Shaw, president of Lilly Bio-Medicines. "We are thrilled with these topline lasmiditan results, which add to more than 25 years of Lilly's research and development of migraine therapies."

The company plans to present data from both studies at scientific meetings and submit results to peer-reviewed journals over the next year. The company has already begun another Phase 3 study, known as GLADIATOR, to evaluate the long-term safety of the drug for the acute treatment of migraine.

The treatment was originally discovered by Lilly in 2005 and later sold the rights to lasmiditan to Massachusetts-based CoLucid Pharmaceuticals Inc, which continued to develop the drug. Lilly recently-completed a $960 million acquisition of CoLucid, a deal which was profiled by Inside INdiana Business Reporter Kylie Veleta in our Life Sciences INdiana e-newsletter.

  • Perspectives

    • The Evolution of Business: From Bottom Line to Value Creation And Impact

      In today's world, consumers want to know how corporations, as a whole, are taking a stand. In fact, customers are 43 percent more likely to purchase a product from a company they know is committed to social value. It's not just consumers pushing this trend. Financial service industry leaders, like KeyBank's Beth Mooney and BlackRock's Larry Fink, are challenging business owners and the C-Suite to rethink their economic impact, environmental footprint and social conscience.



Company Name:
Confirm Email:
INside Edge
Morning Briefing
BigWigs & New Gigs
Life Sciences Indiana
Indiana Connections


  • Most Popular Stories

    • St. Vincent Announces Layoffs

      St. Vincent Health says it has laid off 85 employees throughout the state. In a statement to Inside INdiana Business, St. Vincent cites a rapidly-evolving healthcare environment as a reason for the workforce reduction. 

    • (Rendering provided by the city of Fishers.)

      New Office Building Planned in Fishers

      An $8.5 million office building is planned for the Fishers Certified Tech Park in Hamilton County. Plans call for a multi-story facility with 31,000 square-feet of space. Carmel-based The Hageman Group is partnering with the city on the project. Current properties in the Tech Park include Launch Fishers and the Indiana IoT Lab. President Shane Hageman says...

    • Herff Jones Owner to be Acquired

      The parent of Indianapolis-based Herff Jones will soon be under new ownership. Texas-based Varsity Brands has entered into an agreement to be acquired by Bain Capital Private Equity in Boston. Financial terms of the deal were not disclosed, however CNBC reports it is valued at $2.5 billion.

    • Ranking: Elevate Ventures Top 10 in Early-Stage Investing

      A global financial data and software company ranks Elevate Ventures near the top in a key category. PitchBook says the Indianapolis-based private venture organization is 10th most active among venture capital firms investing in angel-stage or seed-stage companies in the world. Elevate Ventures Chief Executive Officer Chris LaMothe will be a guest this weekend on Inside INdiana Business With Gerry Dick.In 2017, Elevate Ventures invested in 26 early-stage Hoosier businesses and...

    • Free nicotine patches by mail may help smokers quit

      Helping smokers quit may be as easy as mailing them free nicotine-replacement patches, even in the absence of counseling or other support, a new Canadian study shows.